Integrated Wealth Concepts LLC Buys 227 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Integrated Wealth Concepts LLC lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 9.0% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,739 shares of the biopharmaceutical company’s stock after purchasing an additional 227 shares during the quarter. Integrated Wealth Concepts LLC’s holdings in Alnylam Pharmaceuticals were worth $740,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. SVB Wealth LLC bought a new stake in shares of Alnylam Pharmaceuticals during the 1st quarter valued at $27,000. Park Square Financial Group LLC purchased a new position in Alnylam Pharmaceuticals during the fourth quarter worth about $28,000. Whipplewood Advisors LLC grew its position in Alnylam Pharmaceuticals by 208.8% during the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 71 shares in the last quarter. Bessemer Group Inc. grew its position in Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 69 shares in the last quarter. Finally, Washington Trust Advisors Inc. grew its position in Alnylam Pharmaceuticals by 53.5% during the first quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 61 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Barclays boosted their target price on Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the stock an “overweight” rating in a research report on Friday, August 1st. Morgan Stanley boosted their target price on Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the stock an “equal weight” rating in a research report on Friday, August 1st. HC Wainwright restated a “buy” rating and set a $570.00 target price on shares of Alnylam Pharmaceuticals in a research report on Tuesday, September 2nd. Truist Financial assumed coverage on Alnylam Pharmaceuticals in a research report on Monday, July 21st. They set a “buy” rating and a $385.00 target price for the company. Finally, Wolfe Research upgraded Alnylam Pharmaceuticals from an “underperform” rating to a “peer perform” rating in a research report on Monday, August 4th. Twenty-three equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $421.28.

Alnylam Pharmaceuticals Trading Down 0.6%

Shares of ALNY stock opened at $465.89 on Friday. The stock has a market capitalization of $61.07 billion, a PE ratio of -188.62 and a beta of 0.32. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $484.21. The business has a 50-day moving average of $401.46 and a 200 day moving average of $316.84. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.86. The company had revenue of $773.69 million during the quarter, compared to analysts’ expectations of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.Alnylam Pharmaceuticals’s quarterly revenue was up 17.3% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Activity at Alnylam Pharmaceuticals

In related news, Director Colleen F. Reitan sold 18,000 shares of the stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $467.60, for a total transaction of $8,416,800.00. Following the completion of the sale, the director directly owned 775 shares in the company, valued at $362,390. This represents a 95.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Kevin Joseph Fitzgerald sold 1,396 shares of the stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $453.27, for a total value of $632,764.92. Following the sale, the executive vice president owned 22,719 shares of the company’s stock, valued at $10,297,841.13. This represents a 5.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 75,594 shares of company stock worth $33,968,256 over the last three months. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.